Universität zu Köln

Hecht, Markus ORCID: 0000-0003-2082-216X, Hahn, Dennis, Wolber, Philipp, Hautmann, Matthias G., Reichert, Dietmar, Weniger, Steffi, Belka, Claus, Bergmann, Tobias, Goehler, Thomas, Welslau, Manfred, Grosse-Thie, Christina, Guntinas-Lichius, Orlando, von der Gruen, Jens, Balermpas, Panagiotis ORCID: 0000-0001-5261-6446, Orlowski, Katrin, Messinger, Diethelm, Stenzel, Karsten G. and Fietkau, Rainer (2020). Treatment response lowers tumor symptom burden in recurrent and/or metastatic head and neck cancer. BMC Cancer, 20 (1). LONDON: BMC. ISSN 1471-2407

Full text not available from this repository.

Abstract

BackgroundHead and neck squamous cell cancer (HNSCC) frequently causes severe symptoms that may be reduced, when the tumor is successfully treated. The SOCCER trial studied the association of treatment response with patient reported tumor symptom burden in first line treatment of recurrent and/or metastatic HNSCC.MethodsIn this prospective, multi-center, non-interventional trial patients were treated either with platinum-based chemotherapy and cetuximab or radiotherapy and cetuximab. Tumor symptom burden was assessed every four weeks with a questionnaire containing ten visual analogue scales (VAS, range 0-100), which were summarized to the overall VAS score.ResultsFourhundred seventy patients were registered in 97 German centers. A total of 315 patients with at least the baseline and one subsequent questionnaire were available for analysis. Changes in the VAS score were rated as absolute differences from baseline. Negative values indicate improvement of symptoms. The overall VAS score improved significantly at the first post-baseline assessment in responders (-2.13 vs. non-responders +1.15, p=0.048), and even more for the best post-baseline assessment (-7.82 vs. non-responders -1.97, p=0.0005). The VAS for pain (-16.37 vs. non-responders -8.89, p=0.001) and swallowing of solid food (-16.67 vs. non-responders -5.06, p=0.002) improved significantly more in responders (best post-baseline assessment). In the multivariable Cox regression analysis, worse overall VAS scores were associated with worse overall survival (hazard ratio for death 1.12 per 10 points increment on the overall VAS scale, 95% CI 1.05-1.20, p=0.0009).ConclusionIn unselected patients beyond randomized controlled trials, treatment response lowers tumor symptom burden in recurrent and/or metastatic HNSCC.Trial registrationClinicalTrials.gov, NCT00122460. Registered 22 Juli 2005,

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Hecht, Markus UNSPECIFIED orcid.org/0000-0003-2082-216X UNSPECIFIED Hahn, Dennis UNSPECIFIED UNSPECIFIED UNSPECIFIED Wolber, Philipp UNSPECIFIED UNSPECIFIED UNSPECIFIED Hautmann, Matthias G. UNSPECIFIED UNSPECIFIED UNSPECIFIED Reichert, Dietmar UNSPECIFIED UNSPECIFIED UNSPECIFIED Weniger, Steffi UNSPECIFIED UNSPECIFIED UNSPECIFIED Belka, Claus UNSPECIFIED UNSPECIFIED UNSPECIFIED Bergmann, Tobias UNSPECIFIED UNSPECIFIED UNSPECIFIED Goehler, Thomas UNSPECIFIED UNSPECIFIED UNSPECIFIED Welslau, Manfred UNSPECIFIED UNSPECIFIED UNSPECIFIED Grosse-Thie, Christina UNSPECIFIED UNSPECIFIED UNSPECIFIED Guntinas-Lichius, Orlando UNSPECIFIED UNSPECIFIED UNSPECIFIED von der Gruen, Jens UNSPECIFIED UNSPECIFIED UNSPECIFIED Balermpas, Panagiotis UNSPECIFIED orcid.org/0000-0001-5261-6446 UNSPECIFIED Orlowski, Katrin UNSPECIFIED UNSPECIFIED UNSPECIFIED Messinger, Diethelm UNSPECIFIED UNSPECIFIED UNSPECIFIED Stenzel, Karsten G. UNSPECIFIED UNSPECIFIED UNSPECIFIED Fietkau, Rainer UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-318001
DOI:	10.1186/s12885-020-07440-w
Journal or Publication Title:	BMC Cancer
Volume:	20
Number:	1
Date:	2020
Publisher:	BMC
Place of Publication:	LONDON
ISSN:	1471-2407
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language SQUAMOUS-CELL CARCINOMA; CHEMOTHERAPY PLUS CETUXIMAB Multiple languages Oncology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/31800